FIELD: medicine.
SUBSTANCE: group of inventions relates to treatment of movement disorders. Disclosed are: using befiradol or a salt thereof, solvate or ester thereof for preparing a medicament for oral administration to a patient for treating a motor disorder. Said medicinal agent comprises at least one sustained-release pharmaceutical composition containing 1 to 20 wt. % ethyl cellulose of total weight of composition and from 0.25 to 3 mg of befiradol or a salt, solvate or ester thereof (amount is given based on the befiradol base), and provides a mean maximum concentration of befiradol in patient's blood plasma below 15 ng/ml for more than 4 hours after administration. Group of inventions also relates to the use of befiradol in the composition for treating a motor disorder, a composition of the same composition and a corresponding method of treatment. to a minimum.
EFFECT: technical result: side effects of treatment in the form of dizziness and nausea are reduced.
34 cl, 1 dwg, 3 tbl, 3 ex
